CRIS Current Research Information System

NANNI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.632
EU - Europa 3.059
AS - Asia 1.372
AF - Africa 237
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 5
Totale 9.322
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.598
GB - Regno Unito 830
IT - Italia 647
CN - Cina 574
DE - Germania 391
VN - Vietnam 362
SE - Svezia 308
SG - Singapore 225
UA - Ucraina 174
CH - Svizzera 141
IN - India 139
IE - Irlanda 120
RU - Federazione Russa 120
FR - Francia 111
CI - Costa d'Avorio 84
ZA - Sudafrica 67
EE - Estonia 58
TG - Togo 56
BG - Bulgaria 44
BE - Belgio 37
CA - Canada 34
JO - Giordania 18
JP - Giappone 17
NL - Olanda 17
SC - Seychelles 15
RO - Romania 14
FI - Finlandia 13
NG - Nigeria 11
HK - Hong Kong 7
HR - Croazia 7
AT - Austria 6
GR - Grecia 6
CL - Cile 5
ID - Indonesia 5
IR - Iran 5
TR - Turchia 5
AU - Australia 4
EU - Europa 4
AR - Argentina 3
DK - Danimarca 3
EG - Egitto 3
PL - Polonia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
BR - Brasile 2
ES - Italia 2
KR - Corea 2
LB - Libano 2
MD - Moldavia 2
PK - Pakistan 2
PT - Portogallo 2
TW - Taiwan 2
EC - Ecuador 1
IL - Israele 1
IQ - Iraq 1
LU - Lussemburgo 1
MY - Malesia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
Totale 9.322
Salva come PNG Salva come JPEG
Città #
Southend 719
Fairfield 685
Chandler 528
Ashburn 368
Wilmington 317
Woodbridge 310
Houston 302
Ann Arbor 296
Seattle 253
Cambridge 205
Dong Ket 191
Singapore 190
Princeton 175
Shanghai 164
Bologna 157
Dublin 120
Jacksonville 116
Bern 113
Abidjan 84
Westminster 74
Nanjing 67
Padova 66
Lomé 56
Berlin 54
Bremen 47
Sofia 43
Saint Petersburg 42
Beijing 41
Brussels 37
Jinan 37
Shenyang 37
Redwood City 36
San Diego 36
Boardman 30
Milan 30
Nanchang 28
Redmond 28
Hebei 26
Turin 25
Mülheim 24
Changsha 23
Guangzhou 22
Santa Clara 21
Tianjin 21
Jiaxing 19
Ottawa 19
Amman 18
New York 18
Falls Church 17
Bulle 15
Mahé 15
Des Moines 14
London 14
Amsterdam 13
Los Angeles 13
Tokyo 13
Zhengzhou 12
Haikou 11
Abeokuta 10
Helsinki 10
Verona 10
Bühl 9
Dearborn 9
Medford 9
Phoenix 9
Taizhou 9
Kuban 8
Taiyuan 8
Chieti 7
Crocetta 7
Hangzhou 7
Kerpen 7
Leawood 7
Ningbo 7
Crotone 6
Delhi 6
Hong Kong 6
Moscow 6
Norwalk 6
Paris 6
Porto Recanati 6
Toronto 6
Vienna 6
Bo 5
Buffalo 5
Catanzaro 5
Jakarta 5
Kilburn 5
Lanzhou 5
Reggio Nell'emilia 5
Rome 5
San Venanzo 5
Vicenza 5
Argelato 4
Council Bluffs 4
Florence 4
Fuzhou 4
Lausanne 4
Muizenberg 4
Olalla 4
Totale 6.720
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 295
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 237
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 213
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 202
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 189
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 170
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 168
Rethinking herpes simplex virus: the way to oncolytic agents. 156
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 153
CD99 Acts as an Oncosuppressor in Osteosarcoma. 151
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 146
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 146
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 144
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 143
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 142
Virus-like particle display of HER2 induces potent anti-cancer responses 141
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 139
Cancer immunoprevention: from mice to early clinical trials 137
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 136
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors 134
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 131
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 130
Antimetastatic activity of a preventive cancer vaccine. 129
Oncolytic herpes virus retargeted to HER-2. 128
Immunoprevention and immunotherapy of mammary carcinoma 127
Immunological prevention of a multigene cancer syndrome 127
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 127
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 126
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 125
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 124
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 124
Herpesviruses as oncolytic agents 122
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 122
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 122
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 122
Vaccines for tumour prevention 121
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 118
In silico modeling and in vivo efficacy of cancer preventive vaccinations 117
Modeling the competition between lung metastases and the immune system using agents. 116
2011: the immune hallmarks of cancer 114
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 114
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 112
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 112
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 111
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. 110
Preclinical HER-2 Vaccines: From Rodent to Human HER-2 109
New target antigens for cancer immunoprevention 108
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 108
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 108
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 107
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 107
The Promise of Preventive Cancer Vaccines 106
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 106
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 105
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 105
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. 104
The molecular basis of herpesviruses as oncolytic agents. 103
Molecular and cellular biology of rhabdomyosarcoma 102
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 101
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 101
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 101
null 98
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer 96
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 95
Vaccines and other immunological approaches for cancer immunoprevention 95
CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. 94
Preclinical vaccines against mammary carcinoma. 92
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 89
Insulin-like growth factor binding protein 3 as an anti-cancer molecule in Ewing's sarcoma. 87
Cancer biology, what we know and what we don't know. 86
Immunoprevention 83
Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer 78
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 77
Methods of treating bone cancer 63
null 62
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 62
Immunoprevention of cancer 61
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy 57
Immunotherapy 57
Vaccini contro i tumori 57
Cancer immunoprevention 46
Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. 7
Totale 9.596
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.325
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.325
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.183 0 0 34 148 270 237 325 357 346 189 136 141
2020/20211.497 268 94 47 70 30 76 50 158 152 72 65 415
2021/20221.689 161 67 145 82 155 110 51 111 73 115 367 252
2022/20231.986 233 238 106 271 137 137 65 104 261 106 161 167
2023/2024637 22 75 45 51 37 75 35 217 10 27 14 29
2024/2025415 153 223 39 0 0 0 0 0 0 0 0 0
Totale 9.596